Adverse Reactions after Intravenous Iron Infusion among Inflammatory Bowel Disease Patients in the United States, 2010-2014

Inflammatory Bowel Diseases

Volumn 24, Issue 9, 2018, Pages 1801-1807

  Akhuemonkhan, Eboselume ^a   Parian, Alyssa ^a   Carson, Kathryn A ^b   Hutfless, Susan ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

adverse effects; anemia; Crohn's disease; inflammatory bowel diseases; ulcerative colitis

Indexed keywords

FERRIC CARBOXYMALTOSE; FERRIC GLUCONATE; FERUMOXYTOL; HEMOGLOBIN; IRON; IRON DEXTRAN; IRON SACCHARATE; FERRIC ION; MAGNETITE;

ADULT; ADVERSE EVENT; ANAPHYLAXIS; ANEMIA; ARTICLE; BRONCHOSPASM; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; DRUG SAFETY; EPIDEMIOLOGICAL DATA; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; HYPOTENSION; INCIDENCE; INCIDENT RATE RATIO; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEX DIFFERENCE; ULCERATIVE COLITIS; UNITED STATES; YOUNG ADULT; ADOLESCENT; COMPLICATION; INTRAVENOUS DRUG ADMINISTRATION; IRON DEFICIENCY ANEMIA;

ADMINISTRATION, INTRAVENOUS; ADOLESCENT; ADULT; ANEMIA, IRON-DEFICIENCY; FEMALE; FERRIC COMPOUNDS; FERROSOFERRIC OXIDE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; UNITED STATES; YOUNG ADULT;

EID: 85054898806     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1093/ibd/izy063     Document Type: Article

References (45)

1. Kappelman MD, Moore KR, Allen JK, et al. Recent trends in the prevalence of Crohn's disease and ulcerative colitis in a commercially insured US population. Dig Dis Sci. 2013;58:519-25.
2. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46-54. e42; quiz e30.
3. Shivashankar R, Tremaine W, Harmsen S, et al. Updated incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota (1970-2010). Am J Gastroenterol. 2014;109(Suppl 2):S499.
4. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004;126:1504-1517.
5. Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol. 2007;5:1424-9.
6. Wilson A, Reyes E, Ofman J. Prevalence and outcomes of anemia in inflammatory bowel disease: A systematic review of the literature. Am J Med. 2004;116(Suppl):44S-9S.
7. Beigel F, Löhr B, Laubender RP, et al. Iron status and analysis of efficacy and safety of ferric carboxymaltose treatment in patients with inflammatory bowel disease. Digestion. 2012;85:47-54.
8. Gasche C, Berstad A, Befrits R, et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis. 2007;13:1545-53.
9. Avni T, Bieber A, Steinmetz T, et al. Treatment of anemia in inflammatory bowel disease-systematic review and meta-analysis. PLoS One. 2013;8:e75540.
10. Bager P, Befrits R, Wikman O, et al. High burden of iron deficiency and different types of anemia in inflammatory bowel disease outpatients in Scandinavia: A longitudinal 2-year follow-up study. Scand J Gastroenterol. 2013;48:1286-93.
11. Lee TW, Kolber MR, Fedorak RN, et al. Iron replacement therapy in inflammatory bowel disease patients with iron deficiency anemia: A systematic review and meta-analysis. J Crohns Colitis. 2012;6:267-75.
12. Kulnigg S, Gasche C. Systematic review: managing anaemia in Crohn's disease. Aliment Pharmacol Ther. 2006;24:1507-23.
13. Khalil A, Goodhand JR, Wahed M, et al. Efficacy and tolerability of intravenous iron dextran and oral iron in inflammatory bowel disease: A case-matched study in clinical practice. Eur J Gastroenterol Hepatol. 2011;23:1029-35.
14. Antunes CV, Hallack Neto AE, Nascimento CR, et al. Anemia in inflammatory bowel disease outpatients: prevalence, risk factors, and etiology. Biomed Res Int. 2015;2015:728925.
15. Dignass AU, Gasche C, Bettenworth D, et al; European Crohn's and Colitis Organisation (ECCO). European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis. 2015;9:211-22.
16. Koutroubakis IE, Oustamanolakis P, Karakoidas C, et al. Safety and efficacy of total-dose infusion of low molecular weight iron dextran for iron deficiency anemia in patients with inflammatory bowel disease. Dig Dis Sci. 2010;55:2327-31.
17. Bonovas S, Fiorino G, Allocca M, et al. Intravenous versus oral iron for the treatment of anemia in inflammatory bowel disease: A systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2016;95:e2308.
18. Gisbert JP, Gomollón F. Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease. Am J Gastroenterol. 2008;103:1299-307.
19. Filmann N, Rey J, Schneeweiss S, et al. Prevalence of anemia in inflammatory bowel diseases in European countries: A systematic review and individual patient data meta-analysis. Inflamm Bowel Dis. 2014;20:936-45.
20. Nielsen OH, Ainsworth M, Coskun M, et al. Management of iron-deficiency anemia in inflammatory bowel disease: A systematic review. Medicine (Baltimore). 2015;94:e963.
21. Gasche C, Lomer MC, Cavill I, et al. Iron, anaemia, and inflammatory bowel diseases. Gut. 2004;53:1190-7.
22. Wilson A, Reyes E, Ofman J. Prevalence and outcomes of anemia in inflammatory bowel disease: A systematic review of the literature. Am J Med. 2004;116(Suppl 7A):44S-9S.
23. Lugg S, Beal F, Nightingale P, et al. Iron treatment and inflammatory bowel disease: what happens in real practice J Crohns Colitis. 2014;8:876-80.
24. Ott C, Liebold A, Takses A, et al. High prevalence but insufficient treatment of iron-deficiency anemia in patients with inflammatory bowel disease: results of a population-based cohort. Gastroenterol Res Pract. 2012;2012:595970.
25. Kulnigg S, Stoinov S, Simanenkov V, et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: The ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol. 2008;103:1182-92.
26. Stein J, Bager P, Befrits R, et al. Anaemia management in patients with inflammatory bowel disease: routine practice across nine European countries. Eur J Gastroenterol Hepatol. 2013;25:1456-63.
27. Schröder O, Schrott M, Blumenstein I, et al. A study for the evaluation of safety and tolerability of intravenous high-dose iron sucrose in patients with iron deficiency anemia due to gastrointestinal bleeding. Z Gastroenterol. 2004;42:663-7.
28. Muñoz M, Gómez-Ramírez S, García-Erce JA. Intravenous iron in inflammatory bowel disease. World J Gastroenterol. 2009;15:4666-74.
29. Singh A, Patel T, Hertel J, et al. Safety of ferumoxytol in patients with anemia and CKD. Am J Kidney Dis. 2008;52:907-15.
30. Auerbach M, Pappadakis JA, Bahrain H, et al. Safety and efficacy of rapidly administered (one hour) one gram of low molecular weight iron dextran (infed) for the treatment of iron deficient anemia. Am J Hematol. 2011;86:860-2.
31. Laass MW, Straub S, Chainey S, et al. Effectiveness and safety of ferric carboxymaltose treatment in children and adolescents with inflammatory bowel disease and other gastrointestinal diseases. BMC Gastroenterol. 2014;14:184.
32. Wang C, Graham DJ, Kane RC, et al. Comparative risk of anaphylactic reactions associated with intravenous iron products. JAMA. 2015;314:2062-68.
33. Befrits R, Wikman O, Blomquist L, et al. Anemia and iron deficiency in inflammatory bowel disease: An open, prospective, observational study on diagnosis, treatment with ferric carboxymaltose and quality of life. Scand J Gastroenterol. 2013;48:1027-32.
34. Evstatiev R, Marteau P, Iqbal T, et al; FERGI Study Group. Fergicor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology. 2011;141:846-53. e1.
35. Blumenstein I, Dignass A, Vollmer S, et al. Current practice in the diagnosis and management of IBD-associated anaemia and iron deficiency in Germany: The German ANAEMIBD study. J Crohns Colitis. 2014;8:1308-14.
36. Auerbach M, Adamson J, Bircher A, et al. On the safety of intravenous iron, evidence trumps conjecture. Haematologica. 2015;100:e214-e15.
37. Stein J, Hartmann F, Dignass AU. Diagnosis and management of iron deficiency anemia in patients with IBD. Nat Rev Gastroenterol Hepatol. 2010;7:599-610.
38. Hansen LG. Health Research Data for the Real World: The MarketScan Databases. http://images. info. Truvenhealth. biz/Web/TruvenHealthAnalytics /%7B87d8921a-c27c-4382-bd88-d8ec9011de70%7D-2016-Truven-Health- MarketScan-white-paper-for-Life-Sciences. pdf. Accessed August 3, 2016.
39. Keshavarzian A, Mayer L, Salzberg B, et al. A multicenter retrospective experience of infliximab in Crohn's disease patients: infusion reaction rates and treatment persistency. Gastroenterol Hepatol (N Y). 2007;3:381-90.
40. Lees CW, Ali AI, Thompson AI, et al. The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: Analysis of 620 patient-years follow-up. Aliment Pharmacol Ther. 2009;29:286-97.
41. Hamzaoglu H, Cooper J, Alsahli M, et al. Safety of infliximab in Crohn's disease: A large single-center experience. Inflamm Bowel Dis. 2010;16:2109-16.
42. Miheller P, Lakatos PL, Horváth G, et al. Efficacy and safety of infliximab induction therapy in Crohn's disease in central Europe-A Hungarian nationwide observational study. BMC Gastroenterol. 2009;9:66.
43. Rampton D, Folkersen J, Fishbane S, et al. Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management. Haematologica. 2014;99:1671-6.
44. Aksan A, Ik H, Radeke HH, et al. Systematic review with network meta-analysis: comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2017;45:1303-18.
45. US Food and Drug Administration. Drugs@FDA: FDA approved drug products. http://www. Accessdata. fda. gov/scripts/cder/daf/index. cfm. Accessed February 13, 2017.